OS Therapies Stock Forum

$OS Therapies (OSTX.US)$ lots of breakthrough

$OS Therapies (OSTX.US)$
OS Therapies Announces Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Developed Based on Tunable Antibody Drug Conjugate (tADC) Platform Using Proprietary Silicone Linker Platform in Preclinical Models
Folate receptor alpha targeting drug conjugate & hexa silanol exatecan (FRA-H) payloads tested in animal models of ovarian cancer
Strong efficacy for FRA-H in KB and IGROV-1 mouse models of ovarian cancer
Strong safety profile for FRA-H wit...

$OS Therapies (OSTX.US)$
OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment Dose
OS Therapies Incorporated (NYSE:OSTX) ("OS Therapies" or "the Company"), an ADC and Immunotherapy research and clinical-stage biopharmaceutical company, today announced that the last patient (Patient #41) enrolled in the AOST-2121 clinical trial (NCT04974008) of OST-HER2 in recurred, resected Osteosarcoma (OS) - has received its last treatment dos...

$OS Therapies (OSTX.US)$ up up up!
$Serve Robotics (SERV.US)$

$Serve Robotics (SERV.US)$ hope we get a good movement today $OS Therapies (OSTX.US)$

$OS Therapies (OSTX.US)$ 🚀🚀🚀

$OS Therapies (OSTX.US)$
Osteosarcoma is relatively rare, 1,000 cases per year, but more prevalent among children, making it more serious.
Other information:
2% of all childhood cancers
8th most common cancer in children
Most common bone malignancy